Show summary Hide summary
A medication long used to control seizures may also block the first steps in the cascade that leads to Alzheimer’s disease, a new study reports — a finding that, if confirmed, could shift the focus from clearing plaques to preventing them. The research, published in Science Translational Medicine, suggests the drug interferes with production of the most toxic form of amyloid protein in laboratory models and human tissue, raising hopes for very early preventive strategies.
Levetiracetam, marketed for decades under names such as Keppra, is an established anti‑seizure treatment approved by the FDA in 1999 and widely prescribed across age groups. Researchers at Northwestern University investigated whether the drug influences the cellular processes that generate amyloid fragments implicated in Alzheimer’s.
The team found that levetiracetam reduced formation of amyloid‑beta 42 — the particularly aggregation‑prone peptide tied to plaque formation — in animal experiments and in cultured human neurons. The same effect was observed in post‑mortem brain samples from people with Down syndrome, a group at markedly higher risk of developing Alzheimer’s pathology.
Iran crisis raises immediate risks: Trump’s oil-first foreign policy in jeopardy
Aroma Park mass draws community and faith leaders: photos from the gathering
Whereas recently approved Alzheimer’s therapies focus on clearing existing deposits, the Northwestern results point to a different possibility: preventing the toxic peptides from being made in the first place. If a drug can reliably block that early production step, it could delay or diminish downstream events such as tau tangles, inflammation and neuronal loss.
- What the study showed: Levetiracetam lowered production of amyloid‑beta 42 in mice, in human neuronal cultures and in Down syndrome brain tissue.
- Clinical signal: Re‑analysis of prior patient records suggested those taking levetiracetam experienced a modest but statistically significant delay from cognitive decline to death compared with those not on the drug.
- Timing matters: According to the investigators, any preventive benefit would likely require treatment to begin decades before symptoms appear—possibly up to 20 years earlier.
- Limitations: The evidence so far comes from animal models, cells and observational human data; causal proof in people is lacking and randomized clinical trials are needed.
Why this could change prevention thinking
Most current Alzheimer’s treatments target plaques that are already present. By contrast, the new study describes a mechanism that appears to steer neurons away from the biochemical pathway that creates the most harmful amyloid fragments. Interrupting the process upstream could, in theory, reduce the chain reaction that ends in tau aggregation and cell death.
However, the window for such an intervention would be early — long before clinical symptoms become apparent. The researchers emphasize that once significant neurodegeneration has occurred, preventing further peptide production is unlikely to reverse established damage.
Safety, caveats and next steps
The investigators were careful to note several important caveats. Laboratory models do not guarantee human benefit, and the observational analysis cannot establish that levetiracetam directly produced the slower decline seen in some patients. The drug also has known side effects, including drowsiness, dizziness, appetite loss and, in some people, mood or behavioral changes; rare but serious reactions have been reported.
Another practical issue is pharmacokinetics: levetiracetam is rapidly cleared from the body. The research team is developing analogues designed to remain active longer and to more precisely target the molecular pathway identified in this work. Their immediate plans include recruiting people with inherited forms of Alzheimer’s for early‑phase testing.
Key takeaways for readers
- These findings are preliminary and do not justify using levetiracetam off‑label as an Alzheimer’s preventive today.
- The study points to a promising biological target that could lead to preventive drugs, but human trials are required to confirm safety and efficacy.
- Early identification of high‑risk individuals would be crucial if preventative therapy becomes viable.
Funding for the study came from the National Institutes of Health and the Cure Alzheimer’s Fund. Researchers caution that while the results open new avenues for drug development, validated clinical trials will be needed before any change to standard care is warranted.
